311 related articles for article (PubMed ID: 28393455)
1. HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets.
O'Rafferty C; Rooney G; Hagan R; Woolfson M; O'Donghaile D; Fitzgerald J
Transfus Med; 2017 Oct; 27 Suppl 5():369-374. PubMed ID: 28393455
[TBL] [Abstract][Full Text] [Related]
2. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
Levy L; Woodfield DG
N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
[TBL] [Abstract][Full Text] [Related]
3. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial.
Lee EJ; Schiffer CA
Transfusion; 1989 Jun; 29(5):384-9. PubMed ID: 2660333
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
[TBL] [Abstract][Full Text] [Related]
5. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
McVey M; Cserti-Gazdewich CM
Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
[TBL] [Abstract][Full Text] [Related]
6. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience.
Karlström C; Linjama T; Edgren G; Lauronen J; Wikman A; Höglund P
Transfusion; 2019 Mar; 59(3):945-952. PubMed ID: 30575964
[TBL] [Abstract][Full Text] [Related]
7. ABO incompatible platelets: risks versus benefit.
Dunbar NM; Ornstein DL; Dumont LJ
Curr Opin Hematol; 2012 Nov; 19(6):475-9. PubMed ID: 22914587
[TBL] [Abstract][Full Text] [Related]
8. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
[TBL] [Abstract][Full Text] [Related]
9. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients.
Nambiar A; Duquesnoy RJ; Adams S; Zhao Y; Oblitas J; Leitman S; Stroncek D; Marincola F
Blood; 2006 Feb; 107(4):1680-7. PubMed ID: 16269623
[TBL] [Abstract][Full Text] [Related]
10. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
Triulzi DJ; Assmann SF; Strauss RG; Ness PM; Hess JR; Kaufman RM; Granger S; Slichter SJ
Blood; 2012 Jun; 119(23):5553-62. PubMed ID: 22496156
[TBL] [Abstract][Full Text] [Related]
11. Statewide support of thrombocytopenic patients with ABO matched single donor platelets.
Reiss RF; Katz AJ
Transfusion; 1976; 16(4):312-20. PubMed ID: 951726
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
13. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
[TBL] [Abstract][Full Text] [Related]
14. Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.
Elhence P; Chaudhary RK; Nityanand S
Blood Transfus; 2014 Apr; 12(2):180-6. PubMed ID: 24333069
[TBL] [Abstract][Full Text] [Related]
15. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial.
Marsh JC; Stanworth SJ; Pankhurst LA; Kallon D; Gilbertson AZ; Pigden C; Deary AJ; Mora AS; Brown J; Laing ES; Choo LL; Hodge R; Llewelyn CA; Harding K; Sage D; Mijovic A; Mufti GJ; Navarrete CV; Brown CJ
Blood; 2021 Jan; 137(3):310-322. PubMed ID: 33475737
[TBL] [Abstract][Full Text] [Related]
16. Donor selection in platelet transfusion therapy of alloimmunized thrombocytopenic patients.
Duqesnoy RJ
Prog Clin Biol Res; 1978; 28():229-43. PubMed ID: 88057
[No Abstract] [Full Text] [Related]
17. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
[TBL] [Abstract][Full Text] [Related]
18. Impact of Human Leucocyte Antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients.
Kallon D; Navarrete CV; Sage DA; Stanworth S; Mufti GJ; Marsh JCW; Brown CJ
Transfus Med; 2020 Feb; 30(1):23-29. PubMed ID: 31209973
[TBL] [Abstract][Full Text] [Related]
19. Use of in vitro assays in selection of compatible platelet donors.
Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
[TBL] [Abstract][Full Text] [Related]
20. HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening.
Kreuger AL; Mäkelburg ABU; Somers JAE; Tomson B; van de Watering LMG; van der Bom JG; van Kraaij MGJ; Weller CM
Transfusion; 2019 Nov; 59(11):3303-3307. PubMed ID: 31602653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
